We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Key Genes Identified for Leukemia Development

By LabMedica International staff writers
Posted on 25 Jan 2016
Print article
The IVIS Lumina Series III Preclinical in vivo Imaging System
The IVIS Lumina Series III Preclinical in vivo Imaging System (Photo courtesy of Perkin Elmer)
Human leukemia is characterized by the prevalence of recurrent chromosomal translocations, resulting in the generation of chimeric fusion proteins with aberrant oncogenic activities.

Two genes have been identified that are critical to the development of acute myeloid leukemia (AML), the leukemia with the highest mortality rate while drugs that selectively block these genes could be highly effective in treating this type of leukemia.

Scientists at King's College London (UK) and their colleagues used genetic tools to silence the two genes, as well as drugs to block their activity, in mice with AML. The genes Lysine (K)-Specific Demethylase 4C (KDM4C) and Protein Arginine Methyltransferase 1 (PRMT1) ordinarily play a role in translating the genetic information in DNA into healthy cell functions. The team have shown, however, that during leukemia development these enzymes are recruited to enable the transformation of blood cells into cancer cells. Crucially, these genes work in tandem and if either is not fully active, leukemia is not able to develop.

Bioluminescence images were acquired using IVIS Lumina II (Caliper, Perkin Elmer; Waltham, MA, USA). When either gene was silenced, the majority of the mice were still alive at the end of the 60-day experiment, whereas without treatment, the majority died in less than 40 days. By blocking either gene's activity with drugs, which is more relevant to how human patients would be treated; the survival times for mice with AML were also significantly extended. Blocking PRMT1 meant half the mice were still alive after 48 days, compared to 36 days for mice who did not receive treatment. Strikingly, leukemia development was even more effectively suppressed in mice with AML by using a drug to block KDM4C activity instead. All of the mice treated with a KDM4C blocker were still alive at the end of the experiments while the group without treatment succumbed to the disease.

Chi Wai Eric So, PhD, a professor of Leukemia Biology, who led the study, said, “The demonstration of how critical these genes are to cancer transformation and treatment could be highly significant for the design of new drugs. Further work is needed to develop and refine drugs to maximize their effects and so that they are suitable for patients. Clinical trials will then be needed to see how leukemia patients respond to these drugs and how use of them can be optimized.” The study was published on January 11, 2016, in the journal Cancer Cell.

Related Links:

King's College London 
Perkin Elmer


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.